Table 1. .
Baseline demographics and clinical characteristics
| Variable | Median (Interquartile range)/Patients (%) |
|---|---|
| Age at diagnosis of Stage IV | 62.6 years (47.0–71.5) |
| Sex | |
| Male | 37 (48.68%) |
| Female | 39 (51.32%) |
| Primary tumor site | |
| Colon–Rectum | 10 (13.16%) |
| Lung | 35 (46.05%) |
| Upper GI | 6 (7.89%) |
| Breast | 10 (13.16%) |
| Kidney | 4 (5.26%) |
| Othera | 11 (14.47%) |
| Histology of the primary tumor | |
| Adenocarcinoma Squamous cell carcinoma Infiltrating ductal carcinoma |
43 (56.58%) 12 (15.79%) 10 (13.16%) |
| Otherb | 11 (14.47%) |
| Disease free interval | 15.7 months (7.8–25.6) |
| ECOG Performance status | |
| 0 | 43 (56.58%) |
| 1 | 31 (40.79%) |
| 2 | 2 (2.63%) |
| Type of metastases | |
| Synchronous Metachronous |
10 (13.16%) 66 (86.84%) |
| Type of nodal progression | |
| First progression Second or more progression |
37 (48.68%) 39 (51.32%) |
| Previous medical therapies | |
| No | 19 (25.0%) |
| One line | 31 (40.79%) |
| Two lines | 26 (34.21%) |
| Number of treated metastatic nodes | |
| 1 | 61 (80.26%) |
| 2 | 11 (14.47%) |
| 3 | 4 (5.26%) |
| Previous medical therapies for nodal metastases | |
| No | 46 (60.53%) |
| Yes | 30 (39.47%) |
| Previous mediastinal RT No Yes |
65 (85.53%) 11 (14.47%) |
| Presence of extra target disease | |
| No | 41 (53.95%) |
| Yes | 35 (46.05%) |
| BED | 75 Gy (59-86) |
| Adjuvant medical therapies | |
| No | 55 (72.37%) |
| Yes | 21 (27.63%) |
ECOG, Eastern Cooperative Oncology Group; GI, gastrointestinal; RT, radiation therapy.
a
Other primary tumor sites: ovary, salivary gland, endometrium, prostate, soft tissues, oropharynx, thymus and pleura
b
Other primary tumor histologies: clear cell carcinoma, neuroendocrine tumor, mesothelioma, thymoma, sarcoma and adenoid cystic carcinoma